Verdiva Bio Presented Preclinical Data for VRB-103
The company showcased its selective oral amylin peptide analog at the 62nd EASD Annual Meeting in Milan.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Do you believe new pharmaceutical weight loss options will offer reliable alternatives to existing treatments?
Verdiva Bio has revealed new preclinical data for its oral amylin peptide analog, VRB-103, during the 62nd EASD Annual Meeting. The drug is currently in a Phase 1 study and is being explored as both a monotherapy and a combination treatment with VRB-101.
Why it matters
Amylin agonism provides a non-incretin mechanism for treating obesity, potentially offering a vital alternative for patients who do not respond to existing GLP-1 therapies. Verdiva Bio is working to expand options for weight management through its proprietary oral absorption technology.
In vitro testing showed VRB-103 achieved high potency and selectivity for human amylin receptor-1 and -3 versus the calcitonin receptor. This development is based on the 62nd edition of the EASD Annual Meeting scientific proceedings.
The players
Verdiva Bio
A biotechnology firm focused on developing oral peptide analogs for metabolic conditions.
The details
VRB-103 functions as a selective oral amylin peptide analog that utilizes the company's proprietary oral absorption enhancer. The candidate is being evaluated in combination with VRB-101, an oral GLP-1 peptide analog currently undergoing Phase 2 development in the United States.
Timeline
September 28-October 2, 2026: The 62nd EASD Annual Meeting in Milan.
End of 2026: Anticipated release of initial Phase 1 data for VRB-103.
The Big Picture
The presentation follows the precedent of data releases at the European Association for the Study of Diabetes (EASD) Annual Meeting, which is a major forum for new metabolic research.
If successful, this oral medication could eventually provide a non-injectable alternative for patients managing obesity and related metabolic conditions. It aims to serve as a new treatment pathway for those who have not achieved desired outcomes with existing GLP-1 therapies.
The takeaway
The development of non-incretin therapies marks a significant shift in addressing obesity by targeting different metabolic pathways than current standard treatments. Patients and providers should monitor upcoming Phase 1 results for early indications of how this oral analog performs in humans.
What happens next
Verdiva Bio anticipates releasing initial results from the ongoing Phase 1 clinical study of VRB-103 by the end of 2026.
Further reading
For additional context on emerging research, visit the Diabetes section.
More information
For more information on the company portfolio, visit the Verdiva Bio company website.
Live Poll
Do you believe new pharmaceutical weight loss options will offer reliable alternatives to existing treatments?
